503 related articles for article (PubMed ID: 11388794)
1. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
[TBL] [Abstract][Full Text] [Related]
2. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
3. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.
van den Beucken T; van Neer N; Sablon E; Desmet J; Celis L; Hoogenboom HR; Hufton SE
J Mol Biol; 2001 Jul; 310(3):591-601. PubMed ID: 11439026
[TBL] [Abstract][Full Text] [Related]
4. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
Rohrbach F; Gerstmayer B; Biburger M; Wels W
Clin Cancer Res; 2000 Nov; 6(11):4314-22. PubMed ID: 11106249
[TBL] [Abstract][Full Text] [Related]
5. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function.
Kariv I; Truneh A; Sweet RW
J Immunol; 1996 Jul; 157(1):29-38. PubMed ID: 8683128
[TBL] [Abstract][Full Text] [Related]
7. Monovalent antibody scFv fragments selected to modulate T-cell activation by inhibition of CD86-CD28 interaction.
Kolly R; Thiel MA; Herrmann T; Plückthun A
Protein Eng Des Sel; 2007 Feb; 20(2):91-8. PubMed ID: 17289805
[TBL] [Abstract][Full Text] [Related]
8. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis in Herpesvirus saimiri-immortalized T lymphocytes by blocking interaction of CD28 with CD80/CD86.
Akari H; Fukumori T; Iida S; Adachi A
Biochem Biophys Res Commun; 1999 Sep; 263(2):352-6. PubMed ID: 10491296
[TBL] [Abstract][Full Text] [Related]
10. [Construction and characterization of bispecific single-chain antibody fragments SZ-2/SZ-21 against platelet glycoprotein Ib alpha and beta3].
Dai K; An G; Ruan C
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1493-7. PubMed ID: 12509914
[TBL] [Abstract][Full Text] [Related]
11. Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector.
Ziller C; Stoeckel F; Boon L; Haegel-Kronenberger H
Gene Ther; 2002 May; 9(9):537-46. PubMed ID: 11973629
[TBL] [Abstract][Full Text] [Related]
12. Expression, purification, and in vitro refolding of a humanized single-chain Fv antibody against human CTLA4 (CD152).
Chen LH; Huang Q; Wan L; Zeng LY; Li SF; Li YP; Lu XF; Cheng JQ
Protein Expr Purif; 2006 Apr; 46(2):495-502. PubMed ID: 16243538
[TBL] [Abstract][Full Text] [Related]
13. Evidence for the involvement of T cell costimulation through the B-7/CD28 pathway in atherosclerotic plaques from apolipoprotein E knockout mice.
Afek A; Harats D; Roth A; Keren G; George J
Exp Mol Pathol; 2004 Jun; 76(3):219-23. PubMed ID: 15126104
[TBL] [Abstract][Full Text] [Related]
14. Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle.
Giguère JF; Bounou S; Paquette JS; Madrenas J; Tremblay MJ
J Virol; 2004 Jun; 78(12):6222-32. PubMed ID: 15163715
[TBL] [Abstract][Full Text] [Related]
15. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR
Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231
[TBL] [Abstract][Full Text] [Related]
16. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
[TBL] [Abstract][Full Text] [Related]
17. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
18. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.
Mukherjee S; Ahmed A; Nandi D
J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440
[TBL] [Abstract][Full Text] [Related]
19. Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.
Connelly RJ; Hayden MS; Scholler JK; Tsu TT; Dupont B; Ledbetter JA; Kanner SB
Int Immunol; 1998 Dec; 10(12):1863-72. PubMed ID: 9885907
[TBL] [Abstract][Full Text] [Related]
20. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
Lu D; Jimenez X; Witte L; Zhu Z
Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]